Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells.
Cultured endothelial cells derived from human umbilical veins or bovine aorta produce a potent inhibitor of platelet aggregation. The inhibitor is synthesized from sodium arachidonate or or prostaglandin endoperoxides by a microsomal enzyme system. Tranylcypromine, a specific antagonist of prostacyclin synthetase, suppresses production of the inhibitor by endothelial cells. The inhibitor, which is ether extractable, has been identified using a two-step thin-layer radiochromatographic procedure and a synthetic prostaglandin I2 standard. With this procedure, we have shown that human and bovine endothelial cells convert sodium [3H]arachidonate to radiolabeled prostaglandin I2 and 6-keto-prostaglandin F1alpha, as wellas prostaglandin E2. Thus, endothelial cells may be non-thrombogenic in vivo because they synthesize and release prostaglandin I2, a potent inhibitor of platelet aggregation.
D000818:Animals; D001011:Aorta / Q000378:metabolism*; D001792:Blood Platelets / Q000378:metabolism; D002417:Cattle; D002478:Cells, Cultured; D004727:Endothelium / Q000502:physiology; D011464:Epoprostenol / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D010974:Platelet Aggregation; D011247:Pregnancy; D011453:Prostaglandins / Q000096:biosynthesis*; D012701:Serotonin / Q000097:blood; D013347:Subcellular Fractions / Q000378:metabolism; D014020:Tissue Extracts / Q000494:pharmacology; D014191:Tranylcypromine / Q000494:pharmacology; D014471:Umbilical Veins / Q000378:metabolism*
D011453:Prostaglandins; D014020:Tissue Extracts; D012701:Serotonin; D014191:Tranylcypromine; D011464:Epoprostenol